Narcoleptic patients suffer episodes of unwanted or unintended sleep. While these patients often experience excessive sleepiness and bouts of involuntary sleep, often called sleep attacks, they should be distinguished from the symptom of prolonged sleepiness.
Narcolepsy is a heritable central nervous system disorder that is a common cause of sleep disturbance. It is the second most common cause of disabling daytime sleepiness after sleep apnea.
Patients with narcolepsy face various psychosocial and work-related problems throughout their lives. As a result, patients with this disorder often experience progressive difficulty in meeting their economic and social responsibilities. While the symptoms of narcolepsy do not tend to worsen with age, they do interact negatively with other age-related problems and medical conditions. For example, conditions such as chronic obstructive pulmonary disease (COPD), with its well-known capacity to disrupt sleep, can produce sleep deprivation and exacerbate the symptoms of narcolepsy.
Patients with narcolepsy have the additional burden of coping with misperceptions about the causes and the involuntary nature of the symptoms. Common misconceptions, even among healthcare providers, include beliefs that sleep attacks and cataplexy are manifestations of denial and avoidance, and that symptoms can be controlled with behavioral or psychotherapeutic techniques.
While there is no credible evidence to support such ideas, there is a role for psychologic intervention in the management of patients with narcolepsy. Such patients often benefit from participation in professionally supervised support groups that focus on coping skills and identification of community resources.
Narcolepsy affects some 0.03 to 0.06% of the population in western Europe and North America. There is no difference in the prevalence of narcolepsy among men and women, but there may be a higher diagnostic rate in men. The disease typically emerges in the second decade of life and increases in severity through the third or fourth decade.
Non-hereditary cases of narcolepsy are most common in humans, but the narcoleptic trait is also heritable. The risk for narcolepsy among the children of a patient with narcolepsy is several orders of magnitude greater than the risk observed in the general population.
No two people ever seem to experience narcolepsy in the same way – in fact, it can vary greatly at different periods of one's life. Symptoms may begin one at a time, but in later life the symptoms may begin all at once. It can stay the same or it can change for unknown reasons.
Common symptoms include:
Narcoleptics also experience abnormal timing of rapid eye movement (REM) sleep associated with paralysis and hallucinations. Paralysis is due to the same central mechanisms which normally block muscle activity during REM sleep.
Two distinct types of paralysis may occur:
Narcolepsy seems to involve dysregulation of wakefulness and sleep rather than true hypersomnolence. Patients with narcolepsy do not sleep more than normal controls but they are prone to fall asleep throughout the day-night cycle, often at inappropriate times such as at work or while driving.
Diagnosis is based on the classical symptoms: sleepiness, cataplexy, hypnotic hallucinations and sleep paralysis. Abnormal results on a Multiple Sleep Latency Test (MSLT) helps confirm a suspected diagnosis. The MSLT consists of four 20-minute opportunities to nap offered at two hour intervals throughout the day. Patients with narcolepsy fall asleep in approximately five minutes or less, and have two or more transitions into REM sleep during the four opportunities to nap. In contrast, normal subjects have an average sleep latency of 12 to 14 minutes and show no REM sleep on the MSLT.
REM sleep may appear in two or more naps in patients without narcolepsy if:
There is no cure for narcolepsy, and a comprehensive approach to managing the excessive sleepiness is required. The symptoms of narcolepsy are usually controlled with stimulants and drugs that suppress REM sleep. Sound sleep hygiene, attention to other substances and drugs that may disrupt the sleep-wake cycle, and periodic reassessment of symptom severity and of the need for and adequacy of treatment modalities are other important aspects of management. Lifelong therapy frequently is required.
Patients with narcolepsy cannot perform psychomotor tasks or maintain alertness as well as normal controls, even when treated with psychostimulants and REM-sleep-suppressing drugs. Review of multiple studies indicates that patients receiving the maximum recommended doses of stimulant medications rarely reach above 70 to 80% of normal control levels on tests of performance and alertness. Many authorities recommend a goal of obtaining maximum alertness at selected times of the day, for example during work or school hours and while driving, and using scheduled naps to help maintain alertness. Others recommend a goal of maximal or "normal" alertness throughout conventional waking hours. Unfortunately, most data indicate that although daytime sleep episodes can be reduced in most cases, they cannot be completely abolished in all patients.
Several independent investigators have reported beneficial effects by GHB against narcolepsy, with two double-blind studies having been published [Scrima et al, 1989 and 1990; Lammers et al., 1993]. Based on these two reports, there is little doubt that the drug is helpful to narcoleptic patients and several other independent investigators have confirmed the findings.
GHB was used in the 1970s to treat sleep disorders, and some interest in this use continues. Some doctors feel it is the most reliable medication for inducing sleep that exists. It is thought to induce rapid eye movement sleep, decreasing symptoms of narcolepsy. Many prominent doctors have been outspoken about the unnecessary legal restrictions placed on this naturally-occurring substance. Medical use in the treatment of narcolepsy is usually 50mg/kg per day.
The most consistent and least controversial effects are improved cataplexy and improved nocturnal sleep disruption with GHB treatment [Scrima et al., 1990; Broughton and Mamelak, 1980: Bedard et al., 1990]. Further investigations would be needed to confirm a possible beneficial effect for daytime sleepiness. Importantly, GHB's anti-cataplectic effects are clearly mediated by a different mode of action when compared to those produced by antidepressant compounds. As such, patients who do not tolerate classical antidepressant treatment because of side-effects, tolerance or contraindications would not have any other choice if GHB were not available to them.
Your body is a highly complex, interconnected system. Instead of guessing at what might be wrong, let us help you discover what is really going on inside your body based on the many clues it is giving.
Our multiple symptom checker provides in-depth health analysis by The Analyst™ with full explanations, recommendations and (optionally) doctors available for case review and answering your specific questions.